Related Experiment Video
Updated: Mar 15, 2026
14:45
Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
6.7K
Alpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical Application.
1Department of Neurology, 2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310009, China.
Parkinson'S Disease
|September 10, 2016
Summary
Parkinson's disease involves alpha-synuclein protein dysfunction. Research explores targeting this protein for early diagnosis and treatment of this neurodegenerative condition.
Area of Science:
- Neurodegenerative diseases
- Neuropathology
- Molecular biology
Background:
- Parkinson's disease is a progressive neurodegenerative disorder characterized by dopaminergic neuronal loss.
- Neuropathological hallmarks include Lewy bodies and Lewy neurites, primarily composed of aggregated alpha-synuclein protein.
- The exact role of alpha-synuclein in Parkinson's pathogenesis remains unclear, despite genetic links.
Purpose of the Study:
- To review current understanding of alpha-synuclein's role in Parkinson's disease.
- To highlight alpha-synuclein as a potential diagnostic biomarker.
- To discuss therapeutic strategies targeting alpha-synuclein.
Main Methods:
- Literature review of studies on alpha-synuclein and Parkinson's disease.
- Analysis of research on alpha-synuclein aggregation and propagation.
- Examination of current diagnostic and therapeutic approaches.
Main Results:
- Alpha-synuclein aggregation and oligomerization are implicated in Parkinson's disease pathology.
- Various forms of alpha-synuclein appear to be detrimental.
- Genetic variations in the SNCA gene are associated with the disease.
Conclusions:
- Alpha-synuclein dysfunction is central to Parkinson's disease pathogenesis.
- Further research is needed to elucidate the precise mechanisms.
- Alpha-synuclein presents a promising target for future diagnostics and therapies.
Related Concept Videos
01:15Parkinson's Disease: Overview
2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K
01:37Neural Regulation
44.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
44.0K
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:22Lysosomal Hydrolases
4.7K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.7K
01:26Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
03:03Amyloid Fibrils
12.7K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.7K